Search research articles
Contact Us
Filters
Showing results (521-530 of 591) with videos related to
Page
of 60
Sort By:
The Journal of Urology
|
December 21, 2016
Convective Thermal Therapy: Durable 2-Year Results of Randomized Controlled and Prospective Crossover Studies for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Claus G Roehrborn, Steven N Gange, Marc C Gittelman, et al.
The Journal of Urology
|
October 4, 2019
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data
E David Crawford, Przemyslaw W Twardowski, Raoul S Concepcion, et al.
Lancet (London, England)
|
July 19, 2025
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Journal for Immunotherapy of Cancer
|
December 30, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
Douglas G McNeel, Neil H Bander, Tomasz M Beer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2019
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
James L Gulley, Michael Borre, Nicholas J Vogelzang, et al.
Urologic Oncology
|
May 4, 2020
A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trial
Neal D Shore, Christopher M Pieczonka, R Jonathan Henderson, et al.
Future Oncology (London, England)
|
June 4, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 19, 2025
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078]
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
The Journal of Sexual Medicine
|
May 25, 2016
Response and Rebuttal to Editorial Commentary on "Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study"
Kevin T McVary, Steven N Gange, Marc C Gittelman, et al.
The Journal of Sexual Medicine
|
May 1, 2016
Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study
Kevin T McVary, Steven N Gange, Marc C Gittelman, et al.
Page
of 60
Search research articles
Search
Showing results (521-530 of 591) with videos related to
Sort By:
Page
of 60
The Journal of Urology
|
December 21, 2016
Convective Thermal Therapy: Durable 2-Year Results of Randomized Controlled and Prospective Crossover Studies for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Claus G Roehrborn, Steven N Gange, Marc C Gittelman, et al.
The Journal of Urology
|
October 4, 2019
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data
E David Crawford, Przemyslaw W Twardowski, Raoul S Concepcion, et al.
Lancet (London, England)
|
July 19, 2025
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Journal for Immunotherapy of Cancer
|
December 30, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
Douglas G McNeel, Neil H Bander, Tomasz M Beer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2019
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
James L Gulley, Michael Borre, Nicholas J Vogelzang, et al.
Urologic Oncology
|
May 4, 2020
A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trial
Neal D Shore, Christopher M Pieczonka, R Jonathan Henderson, et al.
Future Oncology (London, England)
|
June 4, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 19, 2025
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078]
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
The Journal of Sexual Medicine
|
May 25, 2016
Response and Rebuttal to Editorial Commentary on "Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study"
Kevin T McVary, Steven N Gange, Marc C Gittelman, et al.
The Journal of Sexual Medicine
|
May 1, 2016
Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study
Kevin T McVary, Steven N Gange, Marc C Gittelman, et al.
Page
of 60